Efficacy and safety of loteprednol etabonate versus fluorometholone in the treatment of patients after corneal refractive surgery: a meta-analysis
Tóm tắt
To perform a systematic evaluation of the efficacy and safety of loteprednol etabonate (LE) 0.5% versus fluorometholone (FML) 0.1% for treating patients after corneal refractive surgery with the aim of providing an evidence-based rationale for clinical drug selection. Electronic databases (PubMed, EMBASE, Cochrane Library, Web of Science, WanFang, and CNKI) were searched (from inception to December 2021) for comparative clinical studies that evaluated LE versus FML treatment for post-corneal refractive surgery patients. Meta-analysis was performed using the RevMan 5.3 software. The pooled risk ratio (RR) and weighted mean difference (WMD) with corresponding 95% confidence interval (CI) were calculated. Nine studies with a total sample size of 2677 eyes were included in this analysis. FML 0.1% and LE 0.5% produced a similar incidence of corneal haze within 6 months after surgery (P = 0.13 at 1 month, P = 0.66 at 3 months, and P = 0.12 at 6 months). There was no statistically significant difference between the two groups in terms of the mean logMAR postoperative uncorrected distance visual acuity (WMD: − 0.00; 95% CI: − 0.01 to 0.00; P = 0.29) and spherical equivalent (WMD: 0.01; 95% CI: − 0.01 to 0.03; P = 0.35). LE 0.5% appears to have a higher tendency to reduce the incidence of ocular hypertension compared FML 0.1%, but there was no statistical significance (RR: 0.63; 95% CI: 0.27 to 1.50; P = 0.30). This meta-analysis demonstrated that LE 0.5% and FML 0.1% had comparable efficacy in preventing corneal haze and corticosteroid-induced ocular hypertension, with no difference in visual acuity in patients after corneal refractive surgery.
Tài liệu tham khảo
Holden BA, Fricke TR, Wilson DA, Jong M, Naidoo KS, Sankaridurg P, Wong TY, Naduvilath TJ, Resnikoff S (2016) Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmo 123(5):1036–1042. https://doi.org/10.1016/j.ophtha.2016.01.006
Guo H, Hosseini-Moghaddam SM, Hodge W (2019) Corneal biomechanical properties after SMILE versus FLEX, LASIK, LASEK, or PRK: a systematic review and meta-analysis. BMC Ophthalmo 19(1):167–186. https://doi.org/10.1186/s12886-019-1165-3
Vestergaard AH (2014) Past and present of corneal refractive surgery: a retrospective study of long-term results after photorefractive keratectomy and a prospective study of refractive lenticule extraction. Acta Ophthalmol 92(2):1–21. https://doi.org/10.1111/aos.12450
Fernandez J, Rodriguez-Vallejo M, Martinez J, Tauste A, Pinero DP (2018) Corneal biomechanics after laser refractive surgery: unmasking differences between techniques. J Cataract Refract Surg 44(3):390–398. https://doi.org/10.1016/j.jcrs.2017.10.054
Murueta-Goyena A, Canadas P (2018) Visual outcomes and management after corneal refractive surgery: a review. J Optom 11(2):121–129. https://doi.org/10.1016/j.optom.2017.09.002
O’Brart DP, Shalchi Z, McDonald RJ, Patel P, Archer TJ, Marshall J (2014) Twenty-year follow-up of a randomized prospective clinical trial of excimer laser photorefractive keratectomy. Am J Ophthalmol. https://doi.org/10.1016/j.ajo.2014.06.013
Zamorano-Martin F, Sanchez-Gonzalez JM, Garcia-Lorente M, Rachwani-Anil R, Peraza-Nieves J, Rodriguez-Calvo-de-Mora M, Borroni D, Rocha-de-Lossada C (2021) Laser refractive surgery in pregnant or breastfeeding patients. J Cataract Refract Surg 47(8):1081–1087. https://doi.org/10.1097/j.jcrs.0000000000000606
Margo JA, Munir WM (2016) Corneal haze following refractive surgery: a review of pathophysiology, incidence, prevention, and treatment. Int Ophthalmol Clin 56(2):111–125. https://doi.org/10.1097/IIO.0000000000000112
McGhee CN, Dean S, Danesh-Meyer H (2002) Locally administered ocular corticosteroids: benefits and risks. Drug Saf 25(1):33–55. https://doi.org/10.2165/00002018-200225010-00004
Comstock TL, Decory HH (2012) Advances in corticosteroid therapy for ocular inflammation: loteprednol etabonate. Int J Inflam. https://doi.org/10.1155/2012/789623
Salinger CL, Gordon M, Jackson MA, Perl T, Donnenfeld E, Gilleran K (2015) A retrospective analysis of the postoperative use of loteprednol etabonate gel 0.5% following laser-assisted in situ keratomileusis or photorefractive keratectomy surgery. Clin Ophthalmol 9:2089–2097. https://doi.org/10.2147/OPTH.S94332
Mifflin MD, Leishman LL, Christiansen SM, Sikder S, Hsu M, Moshirfar M (2012) Use of loteprednol for routine prophylaxis after photorefractive keratectomy. Clin Ophthalmol 6:653–659. https://doi.org/10.2147/OPTH.S30282
Holland EJ, Djalilian AR, Sanderson JP (2009) Attenuation of ocular hypertension with the use of topical loteprednol etabonate 0.5% in steroid responders after corneal transplantation. Cornea 28(10):1139–1143. https://doi.org/10.1097/ICO.0b013e3181a3c52f
Thanathanee O, Sriphon P, Anutarapongpan O, Athikulwongse R, Thongphiew P, Rangsin R, Suwan-apichon O (2015) A randomized controlled trial comparing dexamethasone with loteprednol etabonate on postoperative photorefractive keratectomy. J Ocul Pharmacol Ther 31(3):165–168. https://doi.org/10.1089/jop.2014.0107
Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. https://doi.org/10.1371/journal.pmed.1000097
Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, Thomas J (2019) Updated guidance for trusted systematic reviews: a new edition of the cochrane handbook for systematic reviews of interventions. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858
Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629–634. https://doi.org/10.1136/bmj.315.7109.629
Karimian F, Faramarzi A, Fekri S, Mohammad-Rabie H, Najdi D, Doozandeh A, Delfaza-Baher S, Yaseri M (2017) Comparison of loteprednol with fluorometholone after myopic photorefractive keratectomy. J Ophthalmic Vis Res 12(1):11–16. https://doi.org/10.4103/2008-322X.200161
Mifflin MD, Betts BS, Frederick PA, Feuerman JM, Fenzl CR, Moshirfar M, Zaugg B (2017) Efficacy and safety of a 3 month loteprednol etabonate 0.5% gel taper for routine prophylaxis after photorefractive keratectomy compared to a 3 month prednisolone acetate 1% and fluorometholone 0.1% taper. Clin Ophthalmol 11:1113–1118. https://doi.org/10.2147/OPTH.S138272
Li WT, Li H, Wei J (2010) Clinical study on the application of 5 g/L loteprednol etabonate ophthalmic suspension after LASIK. Int J Ophthalmol 10(09):1793–1794. https://doi.org/10.3969/j.issn.1672-5123.2010.09.054
Gao DH, Li KJ, Lu H (2010) Clinical observation of Lotemax on intraocular pressure changes after LASEK surgery. Int J Ophthalmol 10(4):806–807. https://doi.org/10.3969/j.issn.1672-5123.2010.04.071
Luo HL, Zhang L, Tang MF, Lu XH, Wu MQ (2012) Clinical analysis of 0.5% loteprednol etabonate ophthalmic suspension after laser epithelial keratomileusis. J Pract Med 28(15):2519–2521. https://doi.org/10.3969/j.issn.1006-5725.2012.15.019
Mao W, Lu B, Zhang Z, Li C (2012) The short-term comparison of three kinds of cortisteriod eye drops for the provention of DLK after LASIK. Ophthalmol CHN 21(05):336–339
Zhang Y, Chen YG, Xia YJ (2015) Clinical comparison between brachytherapy of 0.5% loteprednol etabonate eye drops and long-term therapy of 0.1% fluorometholone eye drops after LASEK. Chin J Exp Ophthalmol 33(07):646–649. https://doi.org/10.3760/cma.j.issn.2095-0160.2015.07.016
Shokoohi-Rad S, Daneshvar R, Jafarian-Shahri M, Rajaee P (2018) Comparison between betamethasone, fluorometholone and loteprednol etabonate on intraocular pressure in patients after keratorefractive surgery. J Curr Ophthalmol 30(2):130–135. https://doi.org/10.1016/j.joco.2017.11.008
Wilson SE (2012) Corneal myofibroblast biology and pathobiology: generation, persistence, and transparency. Exp Eye Res 99(1):78–88. https://doi.org/10.1016/j.exer.2012.03.018
Baek SH, Chang JH, Choi SY, Kim WJ, Lee JH (1997) The effect of topical corticosteroids on refractive outcome and corneal haze after photorefractive keratectomy. J Refract Surg 13(7):644–652. https://doi.org/10.3928/1081-597X-19971101-11
Vetrugno M, Maino A, Quaranta GM, Cardia L (2001) The effect of early steroid treatment after PRK on clinical and refractive outcomes. Acta Ophthalmol Scand 79(1):23–27. https://doi.org/10.1034/j.1600-0420.2001.079001023.x
Spaeth GL, Monteiro de Barros DS, Fudemberg SJ (2009) Visual loss caused by corticosteroid-induced glaucoma: how to avoid it. Retina 29(8):1057–1061. https://doi.org/10.1097/IAE.0b013e3181b32cfd
Chen M, Gong L, Sun X, Gu Y, He X, Qu J, Wang L, Zhang M, Zhong X (2012) A multicenter, randomized, parallel-group, clinical trial comparing the safety and efficacy of loteprednol etabonate 0.5%/tobramycin 0.3% with dexamethasone 0.1%/tobramycin 0.3% in the treatment of Chinese patients with blepharokeratoconjunctivitis. Curr Med Res Opin 28(3):385–394. https://doi.org/10.1185/03007995.2012.659723
Jones R 3rd, Rhee DJ (2006) Corticosteroid-induced ocular hypertension and glaucoma: a brief review and update of the literature. Curr Opin Ophthalmol 17(2):163–167. https://doi.org/10.1097/01.icu.0000193079.55240.18
Kersey JP, Broadway DC (2006) Corticosteroid-induced glaucoma: a review of the literature. Eye 20(4):407–416. https://doi.org/10.1038/sj.eye.6701895